Co-investigator NCRN clinical trial: INCA trial - A multicentre randomised phase II clinical trial of Inotuzumab Ozogamicin plus Rituximab and CVP (IO-R-CVP) versus Gemcitabine plus Rituximab and CVP (Gem-R-CVP) for the first line treatment of patients with diffuse large B cell lymphoma who are not suitable for anthracycline containing chemotherapy.

  • Kim Linton (Other)

Activity: Internal positions, career professional development, other peer review and other › Other › Research

PeriodOct 2011
Degree of RecognitionInternational